Mirvetuximab soravtansine

Cat. No.:	HY-132258
CAS No.:	1453084-37-1
Molecular Weight:	150000
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-80°C, protect from light

Mirvetuximab soravtansine

BIOLOGICAL ACTIVITY

Description

Mirvetuximab soravtansine (IMGN853) is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage[1].

In Vitro

Mirvetuximab soravtansine (IMGN853; 8 nM; 6 h; IGROV-1 cells) combined with Carboplatin (HY-17393) promotes synergistic growth inhibitory effects and cell cycle perturbations in vitro[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line:	IGROV-1 cells
Concentration:	8 nM; 20 μM (Carboplatin)
Incubation Time:	6 h
Result:	Had almost half of all viable cells accumulating in G2/M.

Western Blot Analysis[1]

Cell Line:	IGROV-1 cells
Concentration:	8 nM; 20 μM (Carboplatin)
Incubation Time:	6 h
Result:	Induced γH2AX expression in IGROV-1 cells and to levels higher than those seen following carboplatin exposure alone.

In Vivo

Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; female severe combined immunodeficient (SCID) mice with patient-derived xenografts) potentiates the antitumor activity of Carboplatin in vivo[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female severe combined immunodeficient (SCID) mice with patient-derived xenografts[1]
Dosage:	5 mg/kg; 80 mg/kg (Carboplatin)
Administration:	Intravenous injection; two consecutive weekly doses
Result:	Suppressed tumor growth and combination therapy induced the greatest degree of tumor growth inhibition.

REFERENCES

[1]. Ponte JF, et, al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016 Dec;18(12):775-784.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA